title: PPARs and LXRs: atherosclerosis goes nuclear.
abstract: Atherosclerosis is the leading cause of mortality in the Western world, and new therapeutics to target the metabolic and inflammatory factors that underlie its pathogenesis are needed. Peroxisome proliferator-activated receptors and liver X receptors are lipid-activated nuclear receptors that regulate systemic glucose and lipid metabolism, and modulate inflammation within the vascular wall. New understanding of their functions in physiology and the development of high-affinity synthetic ligands highlight their potential as targets for the treatment of cardiovascular disease.
authors.affiliation: Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, PO Box 85800, San Diego, CA 92186-5800, USA.
authors.forename: Grant D
authors.initials: GD
authors.lastname: Barish
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Evans
mesh_terms: D000818:Animals; D004268:DNA-Binding Proteins; D006801:Humans; D007536:Isomerism; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors / Q000502:physiology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D004268:DNA-Binding Proteins; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors; D018160:Receptors, Cytoplasmic and Nuclear